MELISSA GUEST: Open Payments
NPI 1023730165 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,702 in 76 payments from 15 companies in 2025. Trend: 2023 $1,790 · 2024 $2,157 · 2025 $1,702
Food & beverage: $1,702
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $272 |
| E.R. Squibb & Sons, L.L.C. | 12 | $233 |
| ABBVIE INC. | 8 | $213 |
| Teva Pharmaceuticals USA, Inc. | 6 | $192 |
| Alkermes, Inc. | 9 | $167 |
| Janssen Pharmaceuticals, Inc | 8 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $105 |
| Supernus Pharmaceuticals, Inc. | 5 | $86 |
| Biogen, Inc. | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $56 |
Products named: REXULTI, COBENFY, VRAYLAR, AUSTEDO XR, ARISTADA, CAPLYTA, Qelbree, SPRAVATO.
Industry payments across UT — which companies pay providers there.
